Zenitar Biotech：Hong Kong IPO Application Lapsed, Core Assets Flonoltinib Maleate and Purinostat Mesylate Under Phase III Registrational Clinical Trials
NewTimeSpace News: According to HKEX disclosures, the Hong Kong Main Board listing application submitted by Chengdu Zenitar Biomedical Technology Co., Ltd. on 13 January 2026 has recently lapsed upon expiry of the six-month validity period. Jefferies and CICC acted as joint sponsors at the time of filing. The Company is a late-clinical-stage biotech firm. Its core candidates Flonoltinib Maleate and Purinostat Mesylate for injection have both entered Phase III registrational clinical trials.
NewTimeSpace News: Information published on the HKEX website shows that the Hong Kong Main Board listing application submitted by Chengdu Zenitar Biomedical Technology Co., Ltd. on 13 January 2026 has recently lapsed after the six-month validity period expired. Jefferies and CICC served as joint sponsors upon submission.
Founded in 2019, Zenitar Biomedical is a late-clinical-stage biotechnology company. It integrates structural biology, artificial intelligence and disease-relevant clinical models to develop small-molecule therapeutics with potential first-in-class or best-in-class profiles. The Company has built a diversified pipeline comprising eight proprietary assets, including two core products (Flonoltinib Maleate and Purinostat Mesylate for injection), another two clinical-stage candidates and four preclinical assets.
Among them, Flonoltinib Maleate is developed for myelofibrosis, while Purinostat Mesylate is indicated for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Both candidates have progressed into Phase III registrational clinical trials.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- NewTimeSpace丨Nearly RMB 1.2 Billion Raised Over 5 Years, Revenue-less Zenitar Biotech Files for Hong Kong IPO
- SSI NEW MATERIAL Secures CSRC Filing Approval, Plans Issuance of Approximately 103.50 Million H-shares with Full Tradability
- SINOMAGS TECH Secures CSRC Filing Approval, Plans Issuance of Approximately 26.89 Million H-shares with Full Tradability Arrangement
